Posted by Michael Wonder on 10 May 2022
FDA approves treatment for COVID-19 in certain hospitalised adults
10 May 2022 - Today, the FDA approved a new indication for Olumiant (baricitinib) for the treatment of COVID-19 in hospitalised adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval.
